OnLife

Phase 2Small molecule

CCentre Georges Francois Leclerc

OnLife is one of 10 small molecule programs targeting Neurotoxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurotoxicityRecruiting

NeurotoxicityPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Neurotoxicity

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

1 2

Naropin

FFresenius Kabi USA, LLC

Approved

1 3

Cymbalta

Jazz Pharmaceuticals

Phase 2

1 4

Decadron

AAspen Global Incorporated

Phase 1

1 5

Zocor

OOrganon and Co

Phase 1

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Robitussin

Pfizer

Preclinical

1 8

Xtandi

Astellas

Preclinical

1 9

OnLife

CCentre Georges Francois Leclerc

Phase 2

1 10

General Anesthetic

IInstitutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurotoxicity1 trial

Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL

Recruiting·CCentre Georges Francois Leclerc·Phase 2·NCT05695313·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OnLife. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OnLife compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OnLife. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Georges Francois Leclerc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentre Georges Francois Leclerc

OnLife

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurotoxicity1 trial

References

Drug Info

Quick Facts

Related News